Jiangsu Bioda Life Science Co Ltd announced that its innovative dialysis vascular graft Circuline® has received a registration certificate from the National Medical Products Administration (NMPA). This marks the official launch of China's first domestically developed dialysis vascular graft, a major milestone for the country's medical device industry.

Founded in 2015 and headquartered in the Chongchuan Shibei High-Tech Zone, Jiangsu Bioda specializes in developing and manufacturing high-end medical devices, including artificial blood vessels and vascular stents. In 2022, the company developed Vasoline, China's first artificial blood vessel, which entered mass production the following year. The newly approved Circuline® dialysis graft was developed by Bioda's wholly-owned subsidiary over the course of seven years, addressing key clinical challenges through extensive testing and continuous refinement.

The Circuline® graft is designed to create arteriovenous fistulas, establishing durable and efficient vascular access for repeated needle insertions required during hemodialysis. Combining the advantages of mainstream dialysis grafts on the market, it offers excellent blood and biocompatibility, flexibility, and puncture resistance. Before approval, the product underwent over 300 randomized clinical trials in China, demonstrating performance comparable to leading US products in terms of patency rates and thrombosis prevention.

"Our 30,000-square-meter production facility in Nantong is prepared to begin mass production of the dialysis graft next year," said Du Guangwu, a senior company representative. "We aim to deliver internationally-advanced dialysis solutions with premium quality, competitive pricing, and attentive service to benefit patients across China."

The Circuline® dialysis graft is developed by Bioda. [Photo/WeChat account: chongchuanonline]